America pouchitis treatment market to Make Great Impact in Near Future by 2025 | with key players like Pfizer, Abbott, Allergan Plc, Bayer, Takeda Pharmaceutical Company Limited, Alfa sigma, Atlantic Healthcare, Tillotts Pharma AG

MRFR Offers a Thorough Analysis of America pouchitis treatment market provides the latest information on the present and the future industry trends, allowing the readers to identify the products and services, hence driving the revenue growth and profitability.

 Market Highlights

The America pouchitis treatment market is expected to grow at a CAGR of 8.34% during the forecast period 2017-2023.

Pouchitis is one of the most common complications of ileal pouch-anal anastomosis (IPAA) surgery and has a significant adverse impact on the quality of life. Pouchitis is an inflammation of the surgically constructed pouch. Various therapies are recommended for the treatment of pouchitis such as antibiotics, budesonide enemas, probiotics, probiotics, butyrate suppositories, bismuth enemas, and others.

Increasing need for ileal pouch-anal anastomosis procedure, long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs), rising prevalence of ulcerative colitis (UC), and increasing geriatric population are the key factors driving the pouchitis treatment market.

Ask for free sample @ https://www.marketresearchfuture.com/sample_request/5254

However, the side effects of the available treatment options and stringent FDA regulations may hinder the growth of the market to an extent. Till now not even a single drug is approved by the FDA for the treatment of pouchitis. However, few are in clinical trials waiting for approval such as Alicaforsen by Atlantic Healthcare plc.

Taste the market data and market information presented through more than 296 market data tables and figures spread over 251 pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Americas pouchitis treatment market research report–forecast till 2023.” 

Key Players in the Americas Pouchitis Treatment Market

Some of key the players in the Americas pouchitis treatment market are AstraZeneca, Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi, B. Braun Medical Inc., Valeant Pharmaceuticals, Sucampo Pharmaceuticals, Ironwood Pharmaceuticals, Inc., Astellas Pharma Inc., Synergy Pharmaceuticals, Inc., Ardelyx, Inc., Sebela Pharmaceuticals, Probi, and others.

Segmentation

The America pouchitis treatment market is segmented on the basis of treatment and end user.

On the basis of the treatment, the market is segmented into antibiotics, probiotics, and others. The antibiotic segment is further sub-segmented into ciprofloxacin, metronidazole, rifaximin, and others.

On the basis of the end -users, the market is segmented into hospitals & clinics, research institutes, and others.

Regional Analysis

On the basis of region, the America pouchitis treatment market is segmented into North America, and South America. North America accounts for a major share owing to the rising cases of pouchitis and high healthcare expenditure. People in this region are more inclined towards quality healthcare that leads to increase in the healthcare spending. Due to rising prevalence of pouchitis, various companies, private organizations, and government associations are also actively participating to improve the treatment options.

The Americas pouchitis market is driven by ongoing extensive research in the inflammatory bowel disease (IBD). The American Gastroenterological Association (AGA) has introduced several new research grants to support investigators studying inflammatory bowel disease (IBD) such as Takeda Pharmaceuticals research scholar awards in IBD, and Pfizer pilot research award in IBD.

Around 30% of patients with ulcerative colitis (UC) undergo colectomy with ileal pouch-anal anastomosis (IPAA) surgery, and up to 50% of patients develop at least one episode of pouchitis. So, rising prevalence of ulcerative colitis is boosting the America pouchitis treatment market. According to the Centers for Disease Control and Prevention, in 2015, around 1.3% of the U.S. adults were diagnosed with inflammatory bowel disease (IBD). The prevalence of ulcerative colitis is reported to be 37 to 246 cases per 100,000 individuals whereas, the incidence rate is found to be 2.2 to 14.3 cases per 100,000 people.

Access Sample Report @ https://www.marketresearchfuture.com/reports/america-pouchitis-treatment-market-5254

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.